Catherine Oakman

Summary

Country: Italy

Publications

  1. pmc Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial
    Lynnette Fernández-Cuesta
    Molecular Carcinogenesis Group, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 8, France
    Breast Cancer Res 14:R70. 2012
  2. pmc Recent advances in systemic therapy: new diagnostics and biological predictors of outcome in early breast cancer
    Catherine Oakman
    Sandro Pitigliani Medical Oncology Unit, Hospital of Prato, Istituto Toscano Tumori, Prato, Italy
    Breast Cancer Res 11:205. 2009
  3. doi request reprint The role of topoisomerase IIalpha and HER-2 in predicting sensitivity to anthracyclines in breast cancer patients
    Catherine Oakman
    Translational Research Unit, Department of Oncology, Hospital of Prato, Istituto Toscano Tumori, Piazza Ospedale 2, 59100 Prato, Italy
    Cancer Treat Rev 35:662-7. 2009
  4. ncbi request reprint Predicting anthracycline benefit: have we made any progress?
    Erica Moretti
    Sandro Pitigliani Medical Oncology Unit, Department of Oncology, Hospital of Prato, Istituto Toscano Tumori, Prato, Italy
    Curr Opin Oncol 21:507-15. 2009
  5. doi request reprint Adjuvant systemic treatment for individual patients with triple negative breast cancer
    Catherine Oakman
    Sandro Pitigliani Medical Oncology Unit, Department of Oncology, Hospital ofPrato, Istituto Toscano Tumori, Piazza Ospedale 2, 59100 Prato, Italy
    Breast 20:S135-41. 2011
  6. doi request reprint Inter- and intra-tumoral heterogeneity in DNA damage evaluated by comet assay in early breast cancer patients
    Francesca Galardi
    Translational Research Unit, Department of Oncology, Hospital of Prato, Istituto Toscano Tumori, Prato, Italy
    Breast 21:336-42. 2012
  7. ncbi request reprint TOP2A protein by quantitative immunofluorescence as a predictor of response to epirubicin in the neoadjuvant treatment of breast cancer
    Erica Moretti
    Sandro Pitigliani Medical Oncology Unit, Hospital of Prato, Istituto Toscano Tumori, Piazza Ospedale 2, 59100, Prato, Italy
    Future Oncol 9:1477-87. 2013
  8. doi request reprint Management of triple negative breast cancer
    Catherine Oakman
    Sandro Pitigliani Medical Oncology Unit, Department of Oncology, Hospital of Prato, Istituto Toscano Tumori, Piazza Ospedale 2, Prato, Italy
    Breast 19:312-21. 2010
  9. doi request reprint Breast cancer assessment tools and optimizing adjuvant therapy
    Catherine Oakman
    Sandro Pitigliani Medical Oncology Unit, Department of Oncology, Hospital of Prato, Istituto Toscano Tumori, Piazza Ospedale 2, 59100 Prato, Italy
    Nat Rev Clin Oncol 7:725-32. 2010
  10. doi request reprint Adjuvant chemotherapy--the dark side of clinical trials. Have we learnt more?
    Catherine Oakman
    Sandro Pitigliani Medical Oncology Unit, Department of Oncology, Hospital of Prato, Tuscany Cancer Institute, Prato, Italy
    Breast 18:S18-24. 2009

Collaborators

Detail Information

Publications15

  1. pmc Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial
    Lynnette Fernández-Cuesta
    Molecular Carcinogenesis Group, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 8, France
    Breast Cancer Res 14:R70. 2012
    ....
  2. pmc Recent advances in systemic therapy: new diagnostics and biological predictors of outcome in early breast cancer
    Catherine Oakman
    Sandro Pitigliani Medical Oncology Unit, Hospital of Prato, Istituto Toscano Tumori, Prato, Italy
    Breast Cancer Res 11:205. 2009
    ..Extensive research continues on predictive gene identification for specific chemotherapeutic agents, particularly the anthracyclines, taxanes and alkylating agents...
  3. doi request reprint The role of topoisomerase IIalpha and HER-2 in predicting sensitivity to anthracyclines in breast cancer patients
    Catherine Oakman
    Translational Research Unit, Department of Oncology, Hospital of Prato, Istituto Toscano Tumori, Piazza Ospedale 2, 59100 Prato, Italy
    Cancer Treat Rev 35:662-7. 2009
    ....
  4. ncbi request reprint Predicting anthracycline benefit: have we made any progress?
    Erica Moretti
    Sandro Pitigliani Medical Oncology Unit, Department of Oncology, Hospital of Prato, Istituto Toscano Tumori, Prato, Italy
    Curr Opin Oncol 21:507-15. 2009
    ..Identification of the individuals to derive this benefit may be guided by predictive biomarkers. This review focuses on the search for biomarkers, particularly focusing on the potential roles for HER-2 and/or topoisomerase IIalpha...
  5. doi request reprint Adjuvant systemic treatment for individual patients with triple negative breast cancer
    Catherine Oakman
    Sandro Pitigliani Medical Oncology Unit, Department of Oncology, Hospital ofPrato, Istituto Toscano Tumori, Piazza Ospedale 2, 59100 Prato, Italy
    Breast 20:S135-41. 2011
    ..This review will focus on systemic chemotherapy in early TNBC, particularly anthracyclines and platinums, and potential predictive tools to guide chemotherapy use...
  6. doi request reprint Inter- and intra-tumoral heterogeneity in DNA damage evaluated by comet assay in early breast cancer patients
    Francesca Galardi
    Translational Research Unit, Department of Oncology, Hospital of Prato, Istituto Toscano Tumori, Prato, Italy
    Breast 21:336-42. 2012
    ..Comet assay warrants further study as a potential clinical tool for identification of tumoral DNA damage and ultimately, individualised use of DNA damaging therapy...
  7. ncbi request reprint TOP2A protein by quantitative immunofluorescence as a predictor of response to epirubicin in the neoadjuvant treatment of breast cancer
    Erica Moretti
    Sandro Pitigliani Medical Oncology Unit, Hospital of Prato, Istituto Toscano Tumori, Piazza Ospedale 2, 59100, Prato, Italy
    Future Oncol 9:1477-87. 2013
    ..Anthracyclines are commonly used in breast cancer, although they lack validated predictive biomarkers. We explored the interaction between TOP2A protein by quantitative immunofluorescence (QIF) and anthracycline sensitivity...
  8. doi request reprint Management of triple negative breast cancer
    Catherine Oakman
    Sandro Pitigliani Medical Oncology Unit, Department of Oncology, Hospital of Prato, Istituto Toscano Tumori, Piazza Ospedale 2, Prato, Italy
    Breast 19:312-21. 2010
    ..Critical to optimal future management are accurate identification of truly triple negative disease and adequately powered prospective TNBC trials to establish treatment efficacy and define predictive biomarkers...
  9. doi request reprint Breast cancer assessment tools and optimizing adjuvant therapy
    Catherine Oakman
    Sandro Pitigliani Medical Oncology Unit, Department of Oncology, Hospital of Prato, Istituto Toscano Tumori, Piazza Ospedale 2, 59100 Prato, Italy
    Nat Rev Clin Oncol 7:725-32. 2010
    ..The presence of drug targets and targetable signaling pathways, rather than molecularly defined subgroups, may ultimately drive treatment decisions...
  10. doi request reprint Adjuvant chemotherapy--the dark side of clinical trials. Have we learnt more?
    Catherine Oakman
    Sandro Pitigliani Medical Oncology Unit, Department of Oncology, Hospital of Prato, Tuscany Cancer Institute, Prato, Italy
    Breast 18:S18-24. 2009
    ..The basal phenotype may be predictive of benefit from DNA damaging agents...
  11. doi request reprint Fulvestrant in the management of postmenopausal women with advanced, endocrine-responsive breast cancer
    Catherine Oakman
    Sandro Pitigliani Medical Oncology Unit, Hospital of Prato, Istituto Toscano Tumori, Piazza Ospedale 2, Prato, Italy
    Future Oncol 7:173-86. 2011
    ..A key issue is identification of patients with ER-positive disease who retain sensitivity to antiestrogen therapy after progression on tamoxifen and/or aromatase inhibitors...
  12. doi request reprint Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA)
    Laura Biganzoli
    Sandro Pitigliani Medical Oncology Unit, Istituto Toscano Tumori, Hospital of Prato, Prato, Italy
    Lancet Oncol 13:e148-60. 2012
    ..Recommendations were updated for screening, primary endocrine therapy, surgery, radiotherapy, neoadjuvant and adjuvant systemic therapy, and metastatic breast cancer...
  13. doi request reprint Uncovering the metabolomic fingerprint of breast cancer
    Catherine Oakman
    Department of Oncology, Hospital of Prato, Istituto Toscano Tumori, Prato, Italy
    Int J Biochem Cell Biol 43:1010-20. 2011
    ..The dominant metabolic pathways and metabolite disturbances associated with malignant transformation of breast cells will be outlined, leading to an overview of potential clinical implications for individuals with breast cancer...
  14. pmc Role of lapatinib in the first-line treatment of patients with metastatic breast cancer
    Catherine Oakman
    Sandro Pitigliani Medical Oncology Unit, Hospital of Prato, Istituto Toscano Tumori, Piazza Ospedale 2, 59100, Prato, Italy
    Cancer Manag Res 2:13-25. 2010
    ..The role of lapatinib in HER2-negative disease is unclear...